VANDA PHARMACEUTICALS INC. Increase (Decrease) in Income Taxes Payable
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Income Taxes Payable of -$2.27 million for the 12-month period ending 2011-12-31, per its 10-K filed 2014-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2014-02-25
- VANDA PHARMACEUTICALS INC. increase (decrease) in income taxes payable for the quarter ending 2011-12-31 was -$2.11M, a 417.95% decline year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in income taxes payable for the quarter ending 2011-09-30 was -$113.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in income taxes payable for the quarter ending 2011-06-30 was -$51.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in income taxes payable for the quarter ending 2011-03-31 was $6.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in income taxes payable for fiscal 2011 was -$2.27M, a 158.13% decline from fiscal 2010.
- VANDA PHARMACEUTICALS INC. increase (decrease) in income taxes payable for fiscal 2010 was $3.90M.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2011-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$2.22M derived: sum of 2 quarters · filed 2014-02-25 | -$2.27M derived: sum of 3 quarters · filed 2014-02-25 | -$2.27M 10-K · filed 2014-02-25 |
| 2011-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$164.00K derived: sum of 2 quarters · filed 2012-11-08 | -$158.00K 10-Q · filed 2012-11-08 | $505.00K derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$45.00K 10-Q · filed 2012-08-03 | $618.00K derived: sum of 3 quarters · filed 2013-02-26 | -$1.91M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $6.00K 10-Q · filed 2012-05-09 | $669.00K derived: sum of 2 quarters · filed 2013-02-26 | -$1.86M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$1.86M derived: sum of 2 quarters · filed 2013-02-26 | $3.90M 10-K · filed 2013-02-26 | |
| 2010-09-30 | -$2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $3.23M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $5.76M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |